Diabetes Mellitus Clinical Trial
Official title:
Relationships Between Mean Plasma Glucose and HbA1c in Compensated and Decompensated Cirrhotic Patients With Hepatogenous Diabetes
The liver plays a crucial role in physiological glycemic control through its involvement in
several glucose metabolism processes, including glycogenogenesis and glycogenolysis. Liver
diseases result in impaired glucose metabolism due to hepatocyte dysfunction, termed as
"hepatogenous diabetes". Abnormal glucose metabolism is found in over 90% of patients with
liver cirrhosis. and clinically significant diabetes is known to occur in 30% to 70% of the
patients.
A cohort study of cirrhotic patients with hepatogenous diabetes reported a relatively low
diabetic complication rate, and the majority of mortality causes were complications related
to liver cirrhosis; furthermore, mortality rate due to diabetic complications were reported
to be low. Nonetheless, the average survival rate following the diagnosis of liver cirrhosis
is rising due to increasing early detection rate and improvements in treatment modalities,
and such rise in survival is expected to result in increased prevalence of hepatogenous
diabetes and its complications. Therefore, it is necessary to formulate an accurate
diagnosis of hepatogenous and to provide appropriate treatment.
Analyses of the Diabetes Control and Complications Trial (DCCT) demonstrated an association
between glycated hemoglobin (HbA1c) and mean plasma glucose concentration in diabetic
patients, and currently, HbA1c is being employed as an appropriate marker in diagnosing
diabetes mellitus and in monitoring the control of mean blood glucose.
The association between mean plasma glucose concentration and HbA1c in cirrhotic patients
has not been clearly established as of yet; however, HbA1c in cirrhotic patients is expected
to be influenced by various factors resulted by liver cirrhosis and splenomegaly, including
rapid erythrocyte turnover rate and other glycation processes.
Therefore, HbA1c may not be an appropriate indicator in the diagnosis of hepatogenous
diabetes or the monitoring of glycemic control; however, no systemic study on this issue has
been performed so far. Therefore, the investigators are aiming to investigate the
association between mean plasma glucose concentration and HbA1c in patients with compensated
or decompensated liver cirrhosis who also have hepatogenous diabetes.
1. Primary end outcome Association between mean plasma glucose concentration and glycated
hemoglobin in patients with compensated or decompensated liver cirrhosis who also have
hepatogenous diabetes
2. Secondary end outcome
1. HbA1c distribution in patients diagnosed with hepatogenous diabetes confirmed by
75-gram oral glucose tolerance test (OGTT)
2. Association between mean preprandial blood glucose concentration and glycated
hemoglobin in patients with compensated or decompensated liver cirrhosis who also
have hepatogenous diabetes
3. Association between mean postprandial blood glucose concentration and glycated
hemoglobin in patients with compensated or decompensated liver cirrhosis who also
have hepatogenous diabetes
4. Association between mean plasma glucose concentration and glycated hemoglobin
according to Child-pugh's classification and liver stiffness severity
5. Factors contributing to discrepancy between mean plasma glucose concentration and
HbA1c in patients with compensated or decompensated liver cirrhosis who also have
hepatogenous diabetes
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |